PharmaMedic /
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
PharmaMedic
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us

#NHS

Tag

The O’Shaughnessy report: how to boost clinical trials in the UK

The O’Shaughnessy report: how to boost clinical trials in the UK

The much anticipated O’Shaughnessy report examining commercial clinical trials in the UK was published at the end of May 2023. Its findings have prompted the UK government to initiate a series of actions, in response to its 27 recommendations, that are designed to make the UK a world leader in this important part of the life sciences industry.

26 Jun 2023
Read More
New drug costs threaten NHS financial stability, says report

New drug costs threaten NHS financial stability, says report

The new report, ‘Promoting population health through pharmaceutical policy: The role of the UK Voluntary Scheme’, produced by researchers at the London School of Economics, London School of Hygiene & Tropical Medicine (LSHTM) and University of York, investigates the costs of prescription medicines to the NHS in England.

21 Jun 2023
Read More
Developments in UK mental health treatments

Developments in UK mental health treatments

With Mental Health Awareness Week 2023 having taken place from 15-21 May and focusing on anxiety, what advances have there been in this field to support those with mental health conditions? We examine the status of mental health therapy demand in the UK and whether the provision of digitally enabled treatments could be one way to help ease waiting times.

23 May 2023
Read More
New Integrated Pathology Unit to speed cancer diagnosis

New Integrated Pathology Unit to speed cancer diagnosis

Cancer diagnosis and treatment are set to be accelerated with the opening of England’s first Integrated Pathology Unit (IPU). The new facility will apply pioneering digital imaging and artificial intelligence to pathology, assisting clinical trial research programmes focused on developing tests for cancer.

17 May 2023
Read More
Will ABPI’s ambitious VPAG plans succeed VPAS?

Will ABPI’s ambitious VPAG plans succeed VPAS?

Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.

15 May 2023
Read More
The 2023 ABPI annual conference focused on growing the Life Sciences

The 2023 ABPI annual conference focused on growing the Life Sciences

The 2023 annual conference of the UK’s Association of the British Pharmaceutical Industry (ABPI) at the end of April had a theme of Growing the UK as a Global Hub for Life Sciences.

9 May 2023
Read More
BIA calls on NICE to update evidence on rare disease medicines

BIA calls on NICE to update evidence on rare disease medicines

New research has found that the public believes a new approach should be adopted for making funding decisions about treatments for rare diseases. The report ‘Rare insights: examining the social values of treating rare diseases’, was commissioned by the UK BioIndustry Association’s (BIA) Rare Disease Industry Group (RDIG).

20 Apr 2023
Read More
Government confirms increase to pharma’s statutory scheme

Government confirms increase to pharma’s statutory scheme

Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.

9 Mar 2023
Read More
Government publishes England’s rare diseases priorities for 2023

Government publishes England’s rare diseases priorities for 2023

The UK government has published a report outlining progress on the Rare Disease Action Plan 2022, as well as details of the priorities of the Rare Disease Framework for 2023.

6 Mar 2023
Read More
Advances in rare disease diagnosis

Advances in rare disease diagnosis

Marking the annual Rare Disease Day on 28 February, this article examines how developments in genomics and healthcare are leading to the diagnosis of many rare diseases and helping to pinpoint the care individual patients need.

28 Feb 2023
Read More

Categories

  • Awards
  • Consultants
  • Events
  • News
    • General
    • Medical Affairs
    • Rare diseases
  • Our Services
  • Regulatory
  • Resources
    • White Paper

Tags

#ABPI #BIA #cancer #ClinicalTrials #drugapprovals #drugpricing #drugregulation #EC #EFPIA #EMA #EU #FDA #HorizonEurope #HTA #innovation #lifesciences #marketaccess #MDR #medicalaffairs #medicaldevice #medicinesaccess #medtech #mentalhealth #mhra #NHS #NICE #patients #pharmaregulation #pre-eclampsia #R&D #rarediseases #regulation #regulatory #research #startups #UKgovernment #ukpharma #ukregulation #VPAS AI Biotech COVID-19 Healthcare medicaldevices Pharma
PharmaMedic
  • Home
  • Join Us
  • Our Vision
  • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
Our Services
  • Start-Up
  • Product Launch
  • Product Development
Legal
  • Privacy Policy
  • Cookie Policy
Contact us
  • T:+44 (0) 208 168 1668
  • US Toll Free:+1 628 201 0911
  • [javascript protected email address]
  • The London Bioscience Innovation Centre (LBIC)
    2 Royal College Street
    London NW1 0NH

©2023 PharmaMedic. All Rights Reserved | Company Registration Number: 07364364 | VAT: 135986768

Powered by FL1 Digital